13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • OMS-I141

    Acronym: 

    OMS-I141

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Breast
    Trial Type Treatment
    Phase Phase II Tumour Stream Breast
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Female Anticipated Start Date 2018-11-01
    Molecular Target Anticipated End Date
    Cancer Type Breast
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Female
    Molecular Target
    Tumour Stream Breast
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date 2018-11-01
    Anticipated End Date

    Trial Summary

    A phase II, open-label study of intratumoural tavokinogene telseplasmid plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple negative breast cancer

    Lay Summary

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Calvary Central Districts Hospital Julie Rowe julie.rowe@calvarycare.org.au 08 8239 9536 Recruiting